NCT02471222View on ClinicalTrials.gov

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Walking ImpairmentMultiple Sclerosis
Interventions
DRUG

ADS-5102

Oral capsules to be administered once daily at bedtime for 4 weeks

OTHER

Placebo

Oral capsules to be administered once daily at bedtime for 4 weeks

Trial Locations (15)

11772

Patchogue

Kirkland

27607

Raleigh

30309

Atlanta

34239

Sarasota

37064

Franklin

44195

Cleveland

55905

Rochester

60062

Northbrook

68506

Lincoln

73104

Oklahoma City

75214

Dallas

80045

Aurora

85018

Phoenix

87131

Albuquerque

Sponsors
All Listed Sponsors
lead

Adamas Pharmaceuticals, Inc.

INDUSTRY

NCT02471222 - Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment | Biotech Hunter | Biotech Hunter